All In Biotech

Drug Trial Radar · NCT07628127

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Verdiva Bio Dev LimitedIndustry
Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

Conditions

  • Obesity
  • Overweight

Interventions

  • VRB-103Drug

    VRB-103 tablets will be administered orally.

  • PlaceboOther

    Placebo tablets will be administered orally.

  • VRB-101Drug

    VRB-101 tablets will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)
  2. Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)
  3. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from BaselineTime frame: Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)
  4. Change in Patient Health Questionnaire-9 (PHQ-9) Scores from BaselineTime frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Australia · Recruiting

  • Nucleus Network

    Melbourne, Australia · Recruiting

  • Veritus

    Melbourne, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.